United States - English - NLM (National Library of Medicine)

soft suds, inc. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

United States - English - NLM (National Library of Medicine)

western first aid safety dba aramark - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - purpose benzalkonium chloride ......first aid antiseptic lidocaine hcl .................topical analgesic uses: • temporary relief of pain associated with minor cuts, scrapes,    and burns • helps protect against harmful bacteria

Canada - English - Health Canada

glaxosmithkline consumer healthcare ulc - diphenhydramine hydrochloride - tablet - 50mg - diphenhydramine hydrochloride 50mg - ethanolamine derivatives

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - hydroxyzine hydrochloride (unii: 76755771u3) (hydroxyzine - unii:30s50ym8og) - for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. as a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. atropine and other belladonna alkaloids are not affected by the drug. hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. the effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. the physician should reassess periodically the usefulness of the drug for the individual patient. oral

United States - English - NLM (National Library of Medicine)

a-s medication solutions - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). oxybutynin chloride is contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. oxybutynin chloride is also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product.

United States - English - NLM (National Library of Medicine)

cardinal health - nebivolol hydrochloride (unii: jgs34j7l9i) (nebivolol - unii:030y90569u) - nebivolol 5 mg - bystolic is indicated for the treatment of hypertension, to lower blood pressure [see clinical studies ( 14.1)]. bystolic may be used alone or in combination with other antihypertensive agents [see drug interactions ( 7)].   lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with bystolic. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the

United States - English - NLM (National Library of Medicine)

unit dose services - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan tablets, usp are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: sumatriptan tablets are contraindicated in patients with: teratogenic effects pregnancy category c: there are no adequate and well-controlled trials in pregnant women. in developmental toxicity studies in rats and rabbits, oral administration of sumatriptan to pregnant animals was associated with embryolethality, fetal abnormalities, and pup mortality. when administered by the intravenous route to pregnant rabbits, sumatriptan was embryolethal. sumatriptan tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of sumatriptan to pregnant rats during the period of organogenesis resulted in an increased incidence of fetal blood vessel (cervicothoracic and umbilical) abnormalities. the highest no-effect dose for embryofetal developmental toxicity in rats was 60 mg/kg/day, or approximately 3 times the maximum re

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol transdermal system (twice-weekly) is indicated for:   when prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. consider estrogen therapy only for women at significant risk of osteoporosis. estradiol transdermal system (twice-weekly) is contraindicated in women with any of the following conditions: estradiol transdermal system (twice-weekly) is not indicated for use in pregnancy. there are no data with the use of estradiol transdermal system (twice-weekly) in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to combined hormonal contraceptives (estrogens and progestins) before conception or during early pregnancy. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to

United States - English - NLM (National Library of Medicine)

boiron - selenium (unii: h6241uj22b) (selenium - unii:h6241uj22b) - juvenile acne with blackheads* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals amercia, inc. - antihemophilic factor, human recombinant (unii: p89dr4ny54) (antihemophilic factor, human recombinant - unii:p89dr4ny54) - antihemophilic factor, human recombinant 250 [iu] in 2 ml - adynovate, antihemophilic factor (recombinant), pegylated, is a human antihemophilic factor indicated in children and adults with hemophilia a (congenital factor viii deficiency) for: - on-demand treatment and control of bleeding episodes - perioperative management - routine prophylaxis to reduce the frequency of bleeding episodes limitation of use adynovate is not indicated for the treatment of von willebrand disease. adynovate is contraindicated in patients who have had prior anaphylactic reaction to adynovate, to the parent molecule (advate), mouse or hamster protein, or excipients of adynovate (e.g. tris, mannitol, trehalose, glutathione, and/or polysorbate 80). risk summary there are no data with adynovate use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with adynovate. it is unknown whether adynovate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the presence of adynovate in human milk, the effect on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for adynovate and any potential adverse effects on the breastfed infant from adynovate or from the underlying maternal condition. safety and efficacy studies have been performed in 91 previously treated, pediatric patients age 1 year to <18 years who received at least one dose of adynovate as part of routine prophylaxis, on-demand treatment of bleeding episodes, or perioperative management. adolescent subjects age 12 to <18 (n=25) were enrolled in the adult and adolescent safety and efficacy trial, and subjects <12 years of age (n=66) were enrolled in a pediatric trial. the safety and efficacy of adynovate in routine prophylaxis and the treatment of bleeding episodes were comparable between children and adults. [see clinical studies (14) ] pharmacokinetic studies in children (<12 years) have demonstrated higher clearance, a shorter half-life and lower incremental recovery of factor viii compared to adults. because clearance (based on per kg body weight) has been demonstrated to be higher in children (<12 years), dose adjustment or more frequent dosing based on per kg body weight may be needed in this population. [see clinical pharmacology (12.3) ] clinical studies of adynovate did not include subjects aged 65 and over. adynovate [antihemophilic factor (recombinant), pegylated] (for intravenous use only) do not attempt to do an infusion to yourself unless you have been taught how by your healthcare provider or hemophilia center. step-by-step instructions for reconstituting adynovate are found at the end of this leaflet. always follow the specific instructions given by your healthcare provider. the steps listed below are general guidelines for using adynovate. if you are unsure of the procedures, please call your healthcare provider before using. call your healthcare provider right away if bleeding is not controlled after using adynovate. your healthcare provider will prescribe the dose that you should take. reconstituted product (after mixing dry product with wet diluent) must be used within 3 hours and cannot be stored or refrigerated. your healthcare provider may need to take blood tests from time to time. talk to your healthcare provider before traveling. plan to bring enough adynovate for your treatment during this time. dispose of all materials, including any leftover reconstituted adynovate product, in an appropriate container. - prepare a clean flat surface and gather all the materials you will need for the infusion. check the expiration date, and let the adynovate warm up to room temperature. wash your hands and put on clean exam gloves. if infusing yourself at home, the use of gloves is optional. - check the expiration date, and let the adynovate warm up to room temperature. - wash your hands and put on clean exam gloves. if infusing yourself at home, the use of gloves is optional. - open the adynovate package by peeling away the lid. remove the adynovate from the package and visually inspect the contents of the product and diluent vial. the adynovate powder should be white to off-white in color and the diluent should not contain particles. do not use if discoloration or particles are seen. - place on a flat surface with the diluent vial on top. the diluent vial has a blue stripe. - with one hand holding the adynovate housing, press down firmly on the diluent vial with the other hand until the system is fully collapsed and the diluent flows down into the adynovate vial. both vials will move into the housing when pressed. if you don't see the diluent transfer to the product vial, press the vials again to assure they are completely inserted. do not remove the blue cap until instructed in a later step. - swirl the adynovate gently and continuously until the adynovate is completely dissolved. do not shake . do not refrigerate after reconstitution . inspect the adynovate solution for particulate matter and discoloration prior to administration. the solution should be clear and colorless in appearance. if not, do not use the solution and notify your healthcare provider immediately. - take off the blue cap from the housing and connect the syringe. be careful to not inject air into the adynovate. - turn over the adynovate so that the vial containing the adynovate solution is on top. draw the adynovate solution into the syringe by pulling back the plunger slowly. if the solution does not draw into the syringe, be sure that both vials are pressed firmly together. the contents of more than one vial may be drawn into a single, appropriately sized syringe if you are using more than one vial of adynovate. - disconnect the syringe from the system. attach the infusion needle to the syringe using a winged (butterfly) infusion set, if available. point the needle up and remove any air bubbles by gently tapping the syringe with your finger and slowly and carefully pushing air out of the syringe and needle. - apply a tourniquet and get the injection site ready by wiping the skin well with an alcohol swab (or other suitable solution suggested by your healthcare provider or hemophilia center). - insert the needle into the vein and remove the tourniquet. slowly infuse the adynovate. do not infuse any faster than 10 ml per minute. - take the needle out of the vein and use sterile gauze to put pressure on the infusion site for several minutes. - remove the peel-off label from blister lid and place it in your logbook. clean any spilled blood with a freshly prepared mixture of 1 part bleach and 9 parts water, soap and water, or any household disinfecting solution. - do not recap the needle. place needle, syringe and adynovate system in a hard-walled sharps container for proper disposal. do not dispose of these supplies in ordinary household trash. important: contact your healthcare provider or local hemophilia treatment center if you experience any problems. takeda pharmaceuticals u.s.a., inc. lexington, ma 02421 u.s. license no. 1898 adynovate® , advate® and baxject® are registered trademarks of baxalta incorporated. adynovate® is a registered trademark of baxalta incorporated. takeda® and the takeda logo® are registered trademarks of takeda pharmaceutical company limited. patented: see www.takeda.com/en-us/patents revised: 3/2023